During the last session, Tourmaline Bio Inc (NASDAQ:TRML)’s traded shares were 0.35 million, with the beta value of the company hitting 2.09. At the end of the trading day, the stock’s price was $16.01, reflecting an intraday gain of 10.26% or $1.49. The 52-week high for the TRML share is $29.79, that puts it down -86.07 from that peak though still a striking 27.8% gain since the share price plummeted to a 52-week low of $11.56. The company’s market capitalization is $411.22M, and the average intraday trading volume over the past 10 days was 0.34 million shares, and the average trade volume was 337.52K shares over the past three months.
Tourmaline Bio Inc (NASDAQ:TRML) trade information
Tourmaline Bio Inc (TRML) registered a 10.26% upside in the last session and has traded in the green over the past 5 sessions. The stock spiked 10.26% in intraday trading to $16.01, hitting a weekly high. The stock’s 5-day price performance is 32.31%, and it has moved by -2.85% in 30 days. Based on these gigs, the overall price performance for the year is -10.36%. The short interest in Tourmaline Bio Inc (NASDAQ:TRML) is 3.23 million shares and it means that shorts have 9.39 day(s) to cover.
The consensus price target of analysts on Wall Street is $50, which implies an increase of 67.98% to the stock’s current value. The extremes of the forecast give a target low and a target high price of $42 and $50 respectively. As a result, TRML is trading at a discount of -212.3% off the target high and -162.34% off the low.
An analysis of the company’s performance over the past 5 years shows that the company’s earnings grew an estimated 8.04%. While earnings are projected to return -19.07% in 2025, the next five years will return -18.85% per annum.
TRML Dividends
Tourmaline Bio Inc is due to release its next quarterly earnings on 2025-Mar-12. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.
Tourmaline Bio Inc (NASDAQ:TRML)’s Major holders
Tourmaline Bio Inc insiders own 22.58% of total outstanding shares while institutional holders control 85.86%, with the float percentage being 110.89%. RA CAPITAL MANAGEMENT, L.P. is the largest shareholder of the company, while 150.0 institutions own stock in it. As of 2024-06-30, the company held over 2.54 million shares (or 9.8699% of all shares), a total value of $32.65 million in shares.
The next largest institutional holding, with 2.22 million shares, is of AVORO CAPITAL ADVISORS LLC’s that is approximately 8.6387% of outstanding shares. At the market price on 2024-06-30, these shares were valued at $28.58 million.
Also, the Mutual Funds coming in first place with the largest holdings of Tourmaline Bio Inc (TRML) shares are VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund and iShares Trust-iShares Russell 2000 ETF. Data provided on Dec 31, 2024 indicates that VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund owns about 647.38 shares. This amounts to just over 2.52 percent of the company’s overall shares, with a $10.36 million market value. The same data shows that the other fund manager holds slightly less at 608.6, or about 2.37% of the stock, which is worth about $9.74 million.
